Investor Overview

Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News

Recent News

Natera Reports Second Quarter 2020 Financial Results  -  8/5/2020
SAN CARLOS, Calif. , Aug. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. More »
New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to Immunotherapy  -  8/3/2020
Prospective phase II study shows personalized ctDNA analysis may be used as a biomarker of efficacy across a broad range of tumor types SAN CARLOS, Calif. , Aug. 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the More »
Natera Announces Second Quarter 2020 Earnings Conference Call  -  7/29/2020
SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . More »
Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE)  -  7/14/2020
SAN CARLOS, Calif. , July 14, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar , Natera's VP of Medical Affairs. More »
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas  -  6/22/2020
Grows capacity to process up to three million tests annually SAN CARLOS, Calif. , June 22, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas , supporting greater More »
Event

Upcoming Events

More events are coming soon.
Events

Past events

Date
Title
Wednesday, 08/05/20 at 4:30 PM EDT

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.